TACSTD2 and non-small cell lung carcinoma: Additionally, the phase III TROPION-Lung01 trial showed that another anti-Trop-2 ADC, datopotamab deruxtecan, provided a PFS benefit over docetaxel in metastatic non-small cell lung cancer (NSCLC) [35].